Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
Company Details
- Employees
- 21
- Founded
- -
- Address
- 18, Heolleung-Ro 569-Gil, Gangnam-Gu, Seoul,06376,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.illimistx.com
- Keywords
- IT Consulting.
- HQ
- Seoul
Illimis Therapeutics Questions
Illimis Therapeutics's website is http://www.illimistx.com
Illimis Therapeutics's LinkedIn profile is https://kr.linkedin.com/company/illimis-therapeutics
Illimis Therapeutics has
21 employees.
View email and phone details for 21
employees at Illimis Therapeutics.
Illimis Therapeutics's industry is
Biotechnology Research
Illimis Therapeutics's top competitors are
Everlab,
Shiftbio Inc.,
Neumirna Therapeutics,
Innovation Office University Of Basel,
뉴로핏 (Neurophet),
Dsc Investment,
Nuclidium Ag,
One Biosciences,
Fortuga Bio,
Lmntic Biotech.
Illimis Therapeutics's categories are Biotechnology Research
Illimis Therapeutics's founding year is 2021
